

Our ref: FOI 950

21st February 2022

FOI 950 RESPONSE

Could you please provide the numbers of patients treated in the last 3 months by the Gastroenterology department (for any gastroenterological condition) with the following biologic drugs:

Total Gastroenterology Patients
Adalimumab - Humira
Adalimumab Biosimilar
Filgotinib
Golimumab
Infliximab - Remicade
Infliximab Biosimilar
Ozanimod
Tofacitinib
Ustekinumab
Vedolizumab

Total Gastroenterology Patients	
Adalimumab - Humira	6
Adalimumab Biosimilar	161
Filgotinib	0
Golimumab	<5
Infliximab - Remicade	0
Infliximab Biosimilar	73
Ozanimod	0
Tofacitinib	5
Ustekinumab	80
Vedolizumab	78

We are unable to provide figures for the past 3 months but as at 10/2/2022 this is the number patients treated with the drugs.

The Trust has a legal duty to protect patient confidentiality and, in line with this duty, the figure <5 has been provided where figures are very low. This is because of the potential risk of identification of an individual. In reaching this decision the Trust has taken into account the small geographical area which the Trust serves and the sensitivity of the information requested. In addition the Trust has taken into account the fact that all information disclosed in response to an FOI is disclosed to the 'world at large' and is published on the Trust website.

S 40 (2) (third party information) of the Freedom of Information Act 2000 has been applied to exempt the redacted information from disclosure. The Trust does not consider the disclosure of the redacted information to be fair to the individuals concerned as there is the potential risk of identification of an individual(s) which they would not expect, and which would therefore breach the fairness element of the first principle of the Data Protection Act 2018.

Contact: FOI.team@southerntrust.hscni.net